Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET

Company Participants

Mike Kelly – Investor Relations

Lonnel Coats – Chief Executive Officer

Jeff Wade – President and Chief Financial Officer

Craig Granowitz – Senior Vice President and Chief Medical Officer

Conference Call Participants

Carly Kenselaar – Citigroup

Yasmeen Rahimi – Piper Sandler

Joseph Stringer – Needham & Company

Operator

Good day, ladies and gentlemen. Welcome to the Lexicon Pharmaceuticals Inc. Third Quarter 2022 Earnings Conference Call. At this time all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on November 09, 2022.

I would now like to turn the conference over to Mike Kelly. Please go ahead, sir.

Mike Kelly

Thank you, Michelle. Good afternoon and welcome to the Lexicon Pharmaceuticals third quarter 2022 financial results conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; and Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer. Earlier this afternoon, Lexicon issued a press release announcing our financial results for the third quarter of 2022, which is available on our website at www.lexpharma.com and through our SEC filings. A webcast of this call, along with the slide presentation, is available on our website. During this call, we will review the information provided in the release, provide a corporate update and then use the remainder of our time to answer your questions.

Before we begin, let me remind you that we'll be making forward-looking statements, including statements relating to the safety, efficacy, regulatory status and therapeutic and commercial potential of sotagliflozin, LX9211 and other drug candidates. These statements may include characterizations of the expected timing and results of clinical trials of sotagliflozin, LX9211 and our other drug candidates and the regulatory status and market opportunity for those programs. This call may also contains forward-looking statements relating to our growth and future operating results, discovery and development of our drug candidates, launch and commercialization plans for any approved products, strategic alliances and intellectual property as well as other matters that are not historical facts or information.

Various risks may cause our actual results to differ materially from those expressed or implied in such forward-looking statements. These risks include uncertainties related to our NDA for sotagliflozin and heart failure and our discussions with the FDA regarding sotagliflozin relating to heart failure and type 1 diabetes; the success of our commercialization efforts with respect to any approved products, the timing and results of clinical trials in preclinical studies of sotagliflozin, LX9211 and our other drug candidates; our dependence upon strategic alliances and other third-party relationships; our ability to obtain patent protection for our discoveries; limitations imposed by patents owned or controlled by third parties; and the requirements of substantial funding to conduct our planned research, development and commercialization activities. For a list and a description of the risks and uncertainties that we face, please see the reports we have filed with the Securities and Exchange Commission.